BioSpace News Archive

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced that management will participate in the following upcoming investor conferences:

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, reported its financial results for the third quarter ended Sept. 30, 2020.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020.

Precision Optics Corporation, Inc. announced that it has scheduled a conference call to discuss first quarter fiscal year 2021 financial results on Thursday, November 12, 2020 at 5:00pm ET.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update.

Exhalation Technology (ETL), based in Cambridge, UK, announced the start of a large clinical study on humans with its novel CoronaCheck™ diagnostic test for Covid-19 in exhaled breath condensate (EBC).

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9th at 8:30 a.m. EST to provide additional details on the clinical and immune response data from the remaining GEN-009 Part B patients to be shared at the 35th Annual Meeting of The Society

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the progress of its clinical programs.

Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that Dan D’Agostino was appointed the company’s Chief Financial Officer, effective November 6, 2020.